

News Release



Date: 06:01:2023

for immediate release

Title: Influenza A/B Test Development Enters Optimisation Phase

Rapid *in vitro* diagnostics specialist, RAPIvD Ltd has announced successful prototype tests in developing a rapid multiplexed influenza A/B lateral flow assay.

The assay has been developed for partner company Gemina Labs, utilising their proprietary immobilisation chemistry platform and has been shown to reliably detect multiple strains of influenza viruses in spiked samples of artificial nasal fluid. It has been developed on a single test strip with no cross-reactivity between A and B strains.

The prototype is being fine-tuned in an optimisation phase prior to transfer to Gemina Labs for pre-clinical performance evaluation with patient samples.

RAPIvD CEO, Dr Robert Porter said. "Our prototype tests have delivered impressive results and the use of Gemina's chemistry has been a key factor in developing a multiplexed strip, with high levels of sensitivity and a considerable reduction in the amount of antibody usage compared to conventional chemistry platforms.

"We aim to improve lateral flow technology by developing assays that are more convenient, accurate and affordable and we're well on the way to achieving those goals for Gemina with this project".

Ends.

RAPIvD Ltd, Exchange Building, Colworth Park, Sharnbrook, Bedfordshire, MK44 1LZ, United Kingdom

RAPIvD Ltd a Company duly incorporated in England and Wales, Company number 11225261. VAT number: 305909992
ISO 13485:2016 Certificate Number: MD 764061

Notes and links:

Gemina Labs: www.geminalabs.com

About RAPIvD: www.rapivd.com	RAPIvD is a pioneer in rapid <i>in vitro</i> diagnostics and provides a range of contract R&D and manufacturing services to the medical, healthcare, wellness, occupational health, industrial, security and veterinary sectors. The company was established in 2018 by Dr Robert Porter, a global leader in the world of bio-diagnostics and particularly, lateral flow technology. Rob was a member of the team that developed the world's first self-use pregnancy test (Clearblue) in the mid-1980s and RAPIvD has its headquarters and laboratory on the same site in Bedfordshire, UK.
Media contact:	Richard Wightman, Head of Marketing & Communications, richard@rapivd.com

RAPIvD Ltd, Exchange Building, Colworth Park, Sharnbrook, Bedfordshire, MK44 1LZ, United Kingdom

RAPIvD Ltd a Company duly incorporated in England and Wales, Company number 11225261. VAT number: 305909992
ISO 13485:2016 Certificate Number: MD 764061